Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP11 Versus US-Xolair and EU-Xolair in Healthy Male Volunteers
NCT05053334Phase 1Completed
- Sponsor
- Syneos Health
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of omalizumab in asthma (3 arms), sponsored by Syneos Health. Primary endpoint: Pharmacokinetic similarity up to 127 Days. Started Feb 2022; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05053334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053334.